Dmitry Samarsky
Dmitry Samarsky, PhD has been at the inception of RNAi technology and drug development - starting in 2001 as Director of Technology Development at Sequitur (acquired by Invitrogen) and (in 2005) as Director of Technology Development at Dharmacon (now part of GE). He then served as VP of Technology Development at RXi Pharmaceuticals, USA (2007-2011), SVP of Technology and International Business Development at RiboBio, China (2011-2016) and, most recently, as Chief Scientific Officer at Silence Therapeutics, Germany/UK (2016-2018).
Dr. Samarsky has authored more than 40 scientific papers, articles, book chapters, patents and patent applications. He has been an invited speaker at more than 100 international conferences, and currently serves on the Scientific Advisory Boards for the OTS (Oligonucleotide Therapeutics Society). Dr. Samarsky received his doctorate in biochemistry and molecular biology from University of Massachusetts, Amherst (1998), followed by a postdoctoral position as an H. Arthur Smith Fellow for Cancer Research in Michael Green's lab at University of Massachusetts Medical School (1998-2001).
Denis Drygin
Branden Ryu
Branden Ryu is the founder, the chief executive officer, and the chairman of BIORCHESTRA.
Branden earned his Ph.D. degree from the Graduate school of medicine at the University of Tokyo and completed the Harvard MIT health science and technology internship program at MGH. Also, he has experience as a researcher at Harvard medical school.
After his research career, he found BIORCHESTRA to focus on developing RNA-based therapeutics in 2016. He has discovered the novel RNA biomarker and invented the novel ASO modality to treat neurodegenerative diseases. Under his leadership, BIORCHESTRA has expanded the new RNA modalities to cure neurological disorders including genetic rare diseases. Based on these scientific results, he has filed more than 70 patent applications since 2017.
Armon Sharei
Anisha D'Souza
Andrew Geall
Andrew Tsonchev
Patrick Bayle
Patrick Bayle is a CISM CISSP, Senior Systems Engineer at Cortex, who spent the first ten years of his career working on the security front lines for one of the largest financial institutions in the world.
Tim Erridge
Unit 42 Vice President Tim Erridge is a highly accomplished cybersecurity innovator who is a recognized expert in driving pragmatic solutions that enable global organizations to protect their networks and data amid today’s faster-than-ever-evolving threat landscape. For more than two decades, he has advocated and advanced intelligence-led cybersecurity strategy and operational programmes across a variety of industries and within large, complex multinationals. A distinguished thought leader in cybersecurity, he frequently shares his insights at industry events and in whitepapers and publications.